---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Renal denervation"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Renal denervation. Topics: FDA approval: Symplicity Spyral radiofrequency system, FDA approval: Paradise ultrasound system, Medicare coverage with evidence development: CMS national coverage decision, CMS assessment of the evidence, and 9 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/renal-denervation"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Renal denervation

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Renal Denervation

<a id="topic-2.2.2.1.8-1"></a>

### FDA approval: Symplicity Spyral radiofrequency system

> “The Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “Decision Date 11/17/2023”

Source: [FDA PMA database, Symplicity Spyral Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026)

<a id="topic-2.2.2.1.8-2"></a>

### FDA approval: Paradise ultrasound system

> “The Paradise Ultrasound Renal Denervation System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
> “Decision Date 11/07/2023”

Source: [FDA PMA database, Paradise Ultrasound Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220023)

<a id="topic-2.2.2.1.8-3"></a>

### Medicare coverage with evidence development: CMS national coverage decision

> “The Centers for Medicare & Medicaid Services (CMS) will cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) (collectively, RDN) for uncontrolled hypertension under Coverage with Evidence Development (CED) according to the provisions in sections (B) and (C) below.”
> “(a) Diagnosis of uncontrolled hypertension (≥ 140 mm Hg systolic blood pressure and > 90 mm Hg diastolic blood pressure) despite active management by a clinician with primary responsibility for blood pressure management.”
> “(c) On lifestyle modifications and stable doses of maximally tolerated guideline-directed medical therapy (GDMT), with assessment of adherence to the prescribed regimen, for at least six weeks before referral for RDN.”
> “At a minimum, patients must be screened for primary aldosteronism, obstructive sleep apnea, and drug or alcohol induced hypertension before referral to RDN.”
> “The primary clinicians must coordinate management of the patient for a minimum of six months before referral for RDN, during which the patient had at least three encounters, with no more than two of the three encounters being virtual.”

Source: [CMS decision memo, renal denervation for uncontrolled hypertension (2025)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=318)

<a id="topic-2.2.2.1.8-4"></a>

### CMS assessment of the evidence

> “We agree that while the evidence for RDN is promising, it does not yet satisfy the reasonable and necessary standard required for coverage under Section 1862(a)(1)(A) of the Social Security Act.”
> “In patients with resistant HTN, findings differed between the two On Med trials. In TRIO, uRDN reduced daytime ASBP statistically, but not meaningfully, more than the sham procedure at 2 months but not at 6 months.”

Source: [CMS decision memo, renal denervation for uncontrolled hypertension (2025)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=318)

<a id="topic-2.2.2.1.8-5"></a>

### Place of renal denervation in resistant hypertension: 2025 AHA/ACC guideline

> “COR 1: All patients with hypertension who are being considered for RDN should be evaluated by a multidisciplinary team with expertise in resistant hypertension and RDN.”
> “While some trials showed a small but significant reduction in 24-hour ambulatory SBP by 3 to 5 mm Hg over the sham arm,”
> “RDN should not be considered as a curative therapy for hypertension or full replacement for antihypertensive drugs.”
> “Given the modest BP-lowering effects of RDN over the sham arm or addition of spironolactone, RDN should be reserved for adults with hypertension who develop intolerable side effects to optimal antihypertensive regimens.”
> “Only 60% to 70% of patients undergoing RDN experienced a meaningful reduction in ambulatory SBP of at least 5 mm Hg in clinical trials.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.8-6"></a>

### Patient selection for renal denervation: 2025 AHA/ACC guideline

> “Patients with stage 2 hypertension (with both office SBP ≥140 mm Hg and office DBP ≥90 mm Hg) in whom BP is not at goal despite taking ≥4 antihypertensive medications at optimal dosages (ACEi/ARB +CCB +thiazide-type diuretics, and MRA)”
> “Patients with stage 2 hypertension (with both office SBP ≥140 mm Hg and office DBP ≥90 mm Hg) who are unable to take antihypertensive medications at the optimal dosages or additional medications”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.8-7"></a>

### Renal denervation recommendation and limitations: 2024 ESC guideline

> “Based on the available evidence, renal denervation may be considered for patients who have uncontrolled, true resistant hypertension with a three-drug combination and who express a preference to undergo renal denervation.”
> “meta-analyses report placebo-corrected systolic BP lowering of approximately 6 mmHg on office BP assessment and 4 mmHg on 24 h ABPM”
> “Because of the lack of outcomes trials, renal denervation cannot reach the Class I indication threshold set by this task force.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.8-8"></a>

### Renal denervation as an additive or alternative option: 2023 ESH guideline

> “Endovascular RDN with radiofrequency energy or high frequency unfocused ultrasound energy represents a treatment option, that is additive or alternative to increasing medication in patients with uncontrolled resistant hypertension confirmed by ABPM after excluding secondary causes of hypertension”
> “To date, no prospective multicenter, blinded, randomized, prospective outcome trial exists for RDN.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.2.1.8-9"></a>

### Ultrasound renal denervation in resistant hypertension: RADIANCE-HTN TRIO trial

> “Eligible patients were switched to a once daily, fixed-dose, single-pill combination of a calcium channel blocker, an angiotensin receptor blocker, and a thiazide diuretic.”
> “Between March 11, 2016, and March 13, 2020, 989 participants were enrolled and 136 were randomly assigned to renal denervation (n=69) or a sham procedure (n=67).”
> “Renal denervation reduced daytime ambulatory systolic blood pressure more than the sham procedure (-8·0 mm Hg [IQR -16·4 to 0·0] vs -3·0 mm Hg [-10·3 to 1·8]; median between-group difference -4·5 mm Hg [95% CI -8·5 to -0·3]; adjusted p=0·022)”

Source: [Azizi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34010611/)

<a id="topic-2.2.2.1.8-10"></a>

### Ultrasound renal denervation without medications: RADIANCE II trial

> “Among 1038 eligible patients, 150 were randomized to ultrasound renal denervation and 74 to a sham procedure (mean age, 55 years [SD, 9.3 years]; 28.6% female; and 16.1% self-identified as Black or African American). The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001)”
> “No major adverse events were reported in either group.”

Source: [Azizi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9975904/)

<a id="topic-2.2.2.1.8-11"></a>

### Radiofrequency renal denervation with medications at 6 months: SPYRAL HTN-ON MED trial

> “The treatment difference in the mean 24-hour ambulatory systolic BP from baseline to 6 months between the RDN group (n = 206; -6.5 ± 10.7 mm Hg) and sham control group (n = 131; -4.5 ± 10.3 mm Hg) was -1.9 mm Hg (95% CI: -4.4 to 0.5 mm Hg; P = 0.12).”
> “RDN was associated with a reduction in office systolic BP compared with sham control at 6 months (adjusted treatment difference: -4.9 mm Hg; P = 0.0015).”

Source: [Kandzari et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37914510/)

<a id="topic-2.2.2.1.8-12"></a>

### Radiofrequency renal denervation with medications at 24 months: SPYRAL HTN-ON MED trial

> “At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.”
> “Clinically adverse events were rare, with no instances of renal artery stenosis through 24 months.”

Source: [Kandzari et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244969/)

<a id="topic-2.2.2.1.8-13"></a>

### Radiofrequency renal denervation with medications at 36 months: SPYRAL HTN-ON MED pilot cohort

> “At 36 months, the ambulatory systolic blood pressure reduction was -18·7 mm Hg (SD 12·4) for the renal denervation group (n=30) and -8·6 mm Hg (14·6) for the sham control group (n=32; adjusted treatment difference -10·0 mm Hg, 95% CI -16·6 to -3·3; p=0·0039).”

Source: [Mahfoud et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35390320/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
